Is Your GLP-1 Provider Safe?
FDA Safety Checker
In February 2026, the FDA issued warning letters to over 30 telehealth companies for misleading marketing of compounded GLP-1 medications. Enter your provider's name below to check their safety record instantly.
Database includes 31 verified providers and 17 FDA-warned companies
Red Flags to Watch For
Guaranteed weight loss claims
Legitimate providers never guarantee specific results. Claims like "lose 30 lbs in 30 days" are a regulatory violation and a sign of deceptive marketing.
No medical evaluation required
Any provider that ships GLP-1 medication without a proper medical evaluation (health history, BMI assessment, contraindication screening) is cutting dangerous corners.
Won't name their pharmacy partner
Legitimate providers transparently disclose which compounding pharmacy prepares their medications. Refusal to share this information is a major red flag.
Claims compounded drugs are "identical" to brand-name
Compounded semaglutide is NOT the same as Wegovy or Ozempic. Any provider claiming equivalence is misleading you and violating FDA regulations.
Prices that seem too good to be true
Compounded semaglutide has real costs (pharmacy, ingredients, clinical oversight). Prices under $100/month for an all-inclusive program warrant scrutiny.
No ongoing medical supervision
Auto-refill programs with no check-ins or dose adjustments are dangerous. GLP-1 medications require titration and monitoring, especially during the first few months.
Aggressive social media advertising
Many FDA-warned companies relied heavily on Instagram and TikTok ads with before/after photos and influencer endorsements. Legitimate providers focus on clinical outcomes.
How We Verify Providers
Our safety verification process examines five key dimensions for every GLP-1 provider in our database:
FDA Enforcement History
We monitor FDA warning letters, enforcement actions, and import alerts related to compounded GLP-1 medications and telehealth companies.
Pharmacy Licensing Verification
We verify whether providers use licensed 503A or 503B compounding pharmacies, and whether those facilities are state-licensed and FDA-registered.
NABP Accreditation Check
We check whether pharmacy partners hold National Association of Boards of Pharmacy accreditation, which indicates adherence to strict quality standards.
Operational Track Record
We assess how long the company has been operating, their BBB rating, online reputation, and consistency of their business practices over time.
Transparency Assessment
We evaluate whether providers disclose their pharmacy partners, medical team credentials, pricing structure, and compounding practices.
FDA Warning Letters Explained
An FDA warning letter is a formal communication from the U.S. Food and Drug Administration notifying a company that it has violated federal law. In the context of compounded GLP-1 medications, these violations typically involve:
- Misleading marketing claims — suggesting compounded semaglutide is identical to, or as effective as, FDA-approved brands like Wegovy or Ozempic
- Unapproved new drug claims— marketing compounded medications for indications they haven't been approved for
- Improper compounding practices — operating without proper pharmacy licenses, inadequate sterility controls, or using unlicensed facilities
- No valid patient-provider relationship — dispensing prescription medications without a proper medical evaluation
Warning letters are public record and typically give companies 15 business days to respond with a corrective action plan. Failure to comply can result in further enforcement actions including product seizures, injunctions, and criminal prosecution.
Frequently Asked Questions
Looking for a Verified GLP-1 Provider?
Every provider in our rankings has been verified for pharmacy licensing, transparent practices, and regulatory compliance.
View Verified Rankings →This tool is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or switching GLP-1 medications. Safety data is compiled from public FDA records, state pharmacy board databases, and our independent research. Last updated April 2026.